ADRB2 and asthma: If cysteinyl-leukotrienes, released from resident or circulating inflammatory cells or even from the ASM itself, are responsible for β2-AR desensitization in asthma, then the concurrent administration of cysteinyl-LT1-R antagonists might represent a useful strategy to improve the response to β2-AR agonists in this disease.